Completed

Prospective Safety and Effectiveness Study of PRK for Myopia With or Without Astigmatism Using the ALLEGRETTO WAVE® EYE-Q Excimer Laser System

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Photorefractive keratectomy (PRK)

+ ALLEGRETTO WAVE EYE-Q excimer laser system

ProcedureDevice
Who is being recruted

Eye Diseases+1

+ Refractive Errors

+ Astigmatism

Over 18 Years
+21 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: August 2012
See protocol details

Summary

Principal SponsorAlcon Research
Last updated: September 30, 2019
Sourced from a government-validated database.Claim as a partner

Study start date: August 1, 2012

Actual date on which the first participant was enrolled.

This was a prospective, multi-center, single group study. Subjects underwent bilateral PRK in which the second eye was treated no sooner than 1 week and no later than 30 days after the first eye's PRK treatment. Subjects were followed for 2 years after surgery. The protocol underwent 4 amendments. The key differences between the protocol versions were clarifications of the planned analyses and adverse event reporting procedures. There were no changes in the inclusion and exclusion criteria or non-adverse event related study assessments between the protocol versions 1-5. Refractive stability of manifest refraction spherical equivalent (MRSE) and manifest refractive cylinder was defined as established when: At least 95% of the treated eyes had a change ≤ 1.0 diopter between manifest refractions performed at any 2 manifest refractions at least 3 months apart The mean rate of change, as determined by a paired analysis, was ≤ 0.5 diopter per year (0.04 D/month) over the same time period The mean rate of change decreased monotonically over time, with a projected asymptote of zero or a rate of change attributable to normal aging The 95% confidence interval for the mean rate of change included zero or a rate of change attributable to normal aging. Refractive stability was assessed for pairs of visits within an interval and was defined to occur at the latter time point of the first interval at which stability was achieved. In the final amendment to the protocol, 3 secondary objectives were made co-primary in response to Agency comments. All endpoints and analyses were modified to match.

Principal SponsorAlcon Research
Last updated: September 30, 2019
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

176 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Eye DiseasesRefractive ErrorsAstigmatismMyopia

Criteria

9 inclusion criteria required to participate
Demonstrated stable refraction for contact lens wearers, as specified in protocol

Less than 0.75 D spherical equivalent (SE) difference between cycloplegic and manifest refractions

Minimum best spectacle corrected visual acuity (BSCVA) in the treated eye of 20/25

Other protocol-defined inclusion criteria may apply

Show More Criteria

12 exclusion criteria prevent from participating
A known sensitivity to medications used for study procedures, including PRK

Acute or chronic disease or illness that would increase the operative risk or confound the outcomes of the study

Dry eye syndrome as determined by the short questionnaire for dry eye syndrome

Females who are pregnant, lactating, or planning a pregnancy during the time course of the study, or have another condition associated with the fluctuation of hormones that could lead to refractive changes

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Photorefractive keratectomy (PRK) surgery using the ALLEGRETTO WAVE EYE-Q excimer laser system for myopic wavefront-optimized ablation

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
CompletedNo study centers